Immuno-Oncology II:
Next Wave IO Targets and Modalities

DefinedHealth unconventional insight | THERAPEUTIC INSIGHT by Defined Health | CANCER PROGRESS by Defined Health

Immuno-Oncology II:
Next Wave IO Targets and Modalities

Moderator:

Jeffrey M. Bockman, PhD, Vice President, Defined Health

Panelists:

- *Kenneth C. Carter, PhD*, President and Chief Executive Officer, NexImmune
- *Alessandra Cesano, MD, PhD*, Chief Medical Officer, NanoString Technologies
- *Thomas F. Gajewski, MD, PhD*, Professor of Medicine, University of Chicago
- *Rachel W. Humphrey, MD*, Chief Medical Officer, CytomX Therapeutics, Inc.
- *Christoph Lengauer, PhD, MBA*, Chief Scientific Officer, Blueprint Medicines
- *Peter Sandor, MD, MBA,* VP, Head of Oncology Therapeutic Area in Marketing Strategy, Astellas Pharma

Non IO v. IO Cancer R&D



Cortellis, Defined Health

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth unconventional insight

THERAPEUTIC INSIGHT by Defined Health

CANCER PROGRESS by Defined Health

Top Targets Include PD1 (Checkpoints) and CD40 and OX40 (Costims)

Checkpoint Programs by Target



Costim Programs by Target



Adis R&D Insight, Thomson Reuters Cortellis

Significant Growth in IO Combination Trials - More Than Doubling 2014 to 2015



Clinicaltrials.gov (Data retrieved Nov 18, 2015), Defined Health

Majority of Industry-Funded IO Combination Trials Sponsored by Majors





Clinicaltrials.gov

Combination Clinical Studies in IO

Phases of All Clinical Stage Combination Trials
n > 400



Indications of All Clinical Stage Combination Trials
n > 400



Clinicaltrials.gov (Data retrieved Nov 18, 2015), Adis Insight, Thomson Reuters Cortellis, Defined Health

Merck Sponsoring Most Checkpoint Trials Compared to Peers



Clinicaltrials.gov, Adis Insight, Thompson Reuters Cortellis

An Incredibly Dynamic Space



FierceBiotech
THE BIOTECH BIOWORLD™

Published

Baxalta dives into CAR-T wit

February 26, 2016 | By Damian Garde

Baxalta ($BXLT), soon to merge with Shire
wading into the world of re-engineering T
signing a deal worth up to $1.6 billion to g
some potential immunotherapies.

Under an agreement with North Carolina's
BioSciences, Baxalta is paying $105 millio
collaborate on 6 so-called CAR-T projects
immune system's natural weapons and re-
in on cancer antigens. Precision BioScienc
for early-stage development in the collabo
in once each therapy reaches Phase II, the

Precision BioSciences is due as much as
milestones, per the agreement, and the cc
and profits 50-50 on any CAR-T therapy li

The underlying assumption is that this approach, which mimics more c
than a single monoclonal antibody, will generate a stronger clinical res
Sym004, which comprises two different antibodies that target distinct,
phase IIb trial in metastatic colorectal cancer. It also has an infectious
arm of Basel, Switzerland-based Roche Holding AG.

Back
imm

January 2

Adicet Bi
round anc
on immun
few montl
been worl

While kee
Jakobovit
Technolo
designed
was inspi
proteome
applicatio

Not surpr
Novartis

A number of
company Kite
made it their p
universal T-ce

genomeweb

Business & Policy | Technology | Research | Clinical | Disease Areas

Home » Clinical & Translational » Companion Diagnostics » NanoString, Merck Partner to Develop C

NanoString, Merck Partner to Develop CDx for Anti-PD-1 Therapy

Feb 29, 2016 | a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – NanoString Technologies announced today that it has signed a collaboration agreement with Merck to develop a companion diagnostic to the pharmaceutical company's anti-PD-1 cancer therapy Keytruda (pembrolizumab).

Under the terms of the deal, NanoString will be responsible for developing, commercializing, and seeking regulatory approval for a diagnostic assay on NanoString's nCounter Dx Analysis System to predict patient response to Keytruda. The company will receive funding from Merck for the development of the diagnostic, and will be eligible for up to $24 million for completing certain near-term milestones, as well as possible additional regulatory milestone payments.

The companies signed a collaboration agreement in May 2015 to develop an assay to evaluate the potential to predict Keytruda's benefit to patients.

"We are excited to expand our collaboration with Merck to develop this novel assay for predicting response to anti-PD-1 therapies such as Keytruda," said NanoString President and CEO Brad Gray in a statement. "We believe this gene signature has the potential to become the basis for a universally available assay that serves as the 'gold standard' for informing treatment with immuno-oncology therapies."

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth unconventional insight
THERAPEUTIC INSIGHT by Defined Health
CANCER PROGRESS by Defined Health

Immunotherapy Offers a Diverse Toolkit of Platforms, Cellular & Molecular Targets



Oncotarget, Vol. 5, No. 24, pp.12472-508 (2014 Dec 30)

Cancer Progress by Defined Health
New York, NY | March 8-9, 2016

DefinedHealth unconventional insight

THERAPEUTIC INSIGHT by Defined Health

CANCER PROGRESS by Defined Health